ÜBER DIESE EPISODE
First treatment approved for Alexander disease; Hyrnuo and Etcamah are approved for lung cancer and breast cancer, respectively; Pelacarsen misses endpoint in the phase 3 HORIZON trial, and atogepant shows promise from relieving menstrual migraines.
Englisch
Vereinigte Staaten
TRANSKRIPT 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
VERGANGENE FOLGEN SUCHEN
Vorhandene Folgen von MPR Weekly Dose durchsuchen.
WEITERE EPISODEN IN DIESEM PODCAST
Moderna's mRNA influenza vaccine gains FDA approval; approvals for prostate cancer, narcolepsy type 1 and Mucinex 12HR; and peanut allergy treatment gains Fast Track status.
A new treatment is approved to reduce proteinuria in adults with primary immunoglobulin A nephropahty; a swimmer's ear treatment and the thyroid hormone replacement therapy Amerithroid are now available; Casgevy approval expanded include pediatrics; and a lupus treatment is granted breakthrough sta…
The latest on the multistate cyclospora outbreak; Lipfendra approved to reduce low-density lipoprotein cholesterol in adults with hypercholesterolemia; subcutaneous starting dose regimen approved for Leqembi; NDA accepted for oral sleep apnea treatment; and Revtorpyk combination approved for advanc…
An over-the-counter acetaminophen/naproxen sodium fixed-dose tablet gains approval; Simtriyo approved for ADHD; Xocova approved for COVID-19 postexposure prophylaxis; A new contraceptive patch is approved; and Furoscix ReadyFlow approval is expanded to treat edema in CHF, CKD.
Kalshi start clinical trials, FDA approvals prediction market; positive results shared for triple hormone therapy retatrutide; Jideytro gains approval in advanced or metastatic ROS1-positive NSCLC; a smart toilet seat hits the market to measure your vitals; and the FDA accepts an application for pr…
Rechtliche Hinweise: Der auf dieser Seite eingebettete Podcast und das Bildmaterial stammen von MPR Weekly Dose, das Eigentum seines Eigentümers ist und nicht mit Listen Notes, Inc. verbunden ist oder von diesen unterstützt wird.
BEARBEITEN
Vielen Dank, dass Sie uns helfen, die Podcast-Datenbank auf dem neuesten Stand zu halten.
